CA2273807A1 - Utilisation d'antagonistes du recepteur nk-1 dans le traitement des troubles schizophreniques - Google Patents

Utilisation d'antagonistes du recepteur nk-1 dans le traitement des troubles schizophreniques Download PDF

Info

Publication number
CA2273807A1
CA2273807A1 CA002273807A CA2273807A CA2273807A1 CA 2273807 A1 CA2273807 A1 CA 2273807A1 CA 002273807 A CA002273807 A CA 002273807A CA 2273807 A CA2273807 A CA 2273807A CA 2273807 A1 CA2273807 A1 CA 2273807A1
Authority
CA
Canada
Prior art keywords
phenyl
methyl
treatment
receptor antagonist
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002273807A
Other languages
English (en)
Inventor
Raymond Baker
Neil Roy Curtis
Jason Matthew Elliott
Timothy Harrison
Gregory John Hollingworth
Philip Stephen Jackson
Janusz Jozef Kulagowski
Nadia Melanie Rupniak
Eileen Mary Seward
Christopher John Swain
Brian John Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9625051A external-priority patent/GB9625051D0/en
Priority claimed from GB9701459A external-priority patent/GB9701459D0/en
Priority claimed from GB9713715A external-priority patent/GB9713715D0/en
Priority claimed from GBGB9716491.7A external-priority patent/GB9716491D0/en
Priority claimed from GBGB9721191.6A external-priority patent/GB9721191D0/en
Application filed by Individual filed Critical Individual
Publication of CA2273807A1 publication Critical patent/CA2273807A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Abstract

La présente invention a pour objet l'utilisation d'un antagoniste du récepteur NK-1, à action prolongée, agissant sur le système nerveux central; et à administration par voie orale, dans la fabrication d'un médicament prévu pour être administré par voie orale permettant de traiter ou de prévenir les troubles schizophréniques. L'invention traite également de procédés de traitement à l'aide d'un antagoniste du récepteur NK-1 et de compositions pharmaceutiques comprenant cet antagoniste.
CA002273807A 1996-12-02 1997-11-25 Utilisation d'antagonistes du recepteur nk-1 dans le traitement des troubles schizophreniques Abandoned CA2273807A1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB9625051A GB9625051D0 (en) 1996-12-02 1996-12-02 Therapeutic agents
GB9701459A GB9701459D0 (en) 1997-01-24 1997-01-24 Therapeutic agents
GB9713715A GB9713715D0 (en) 1997-06-27 1997-06-27 Therapeutic agents
GBGB9716491.7A GB9716491D0 (en) 1997-08-04 1997-08-04 Therapeutic agents
GB9721191.6 1997-10-07
GB9701459.1 1997-10-07
GB9713715.2 1997-10-07
GBGB9721191.6A GB9721191D0 (en) 1997-10-07 1997-10-07 Therapeutic use
GB9716491.7 1997-10-07
GB9625051.9 1997-10-07
PCT/EP1997/006691 WO1998024445A1 (fr) 1996-12-02 1997-11-25 Utilisation d'antagonistes du recepteur nk-1 dans le traitement des troubles schizophreniques

Publications (1)

Publication Number Publication Date
CA2273807A1 true CA2273807A1 (fr) 1998-06-11

Family

ID=27517389

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002273807A Abandoned CA2273807A1 (fr) 1996-12-02 1997-11-25 Utilisation d'antagonistes du recepteur nk-1 dans le traitement des troubles schizophreniques

Country Status (5)

Country Link
EP (1) EP0942735A1 (fr)
JP (1) JP2001505881A (fr)
AU (1) AU732633B2 (fr)
CA (1) CA2273807A1 (fr)
WO (1) WO1998024445A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007375A1 (fr) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Utilisation d'antagonistes du recepteur nk-1 pour le traitement de troubles du comportement agressifs
AU738047B2 (en) * 1997-08-04 2001-09-06 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating mania
WO1999064010A1 (fr) * 1998-06-11 1999-12-16 Merck Sharp & Dohme Limited Utilisation d'un antagoniste du recepteur nk-1 dans le traitement des troubles psychiatriques
ES2150378B1 (es) * 1998-08-07 2001-07-01 Esteve Labor Dr Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.
WO2005002577A1 (fr) 2003-07-03 2005-01-13 F. Hoffmann-La Roche Ag Antagonistes doubles des recepteurs nk1/nk3 pour traiter la schizophrenie
CA2676357A1 (fr) 2007-01-24 2008-07-31 Glaxo Group Limited Nouvelles compositions pharmaceutiques

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
CA2099233A1 (fr) * 1992-06-29 1993-12-30 Conrad P. Dorn Antagonistes du recepteur de la tachykinine a base de morpholine et de thiomorpholine
US5496833A (en) * 1993-04-13 1996-03-05 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists
IL111002A (en) * 1993-09-22 1998-09-24 Glaxo Group Ltd History of piperidine, their preparation and the pharmaceutical preparations containing them
JP3071467B2 (ja) * 1993-12-29 2000-07-31 メルク シヤープ エンド ドーム リミテツド 置換モルホリン誘導体およびその治療剤としての使用
PT777659E (pt) * 1994-08-15 2001-09-28 Merck Sharp & Dohme Derivados de morfolina e sua utilizacao como agentes terapeuticos

Also Published As

Publication number Publication date
AU5753098A (en) 1998-06-29
AU732633B2 (en) 2001-04-26
WO1998024445A1 (fr) 1998-06-11
EP0942735A1 (fr) 1999-09-22
JP2001505881A (ja) 2001-05-08

Similar Documents

Publication Publication Date Title
US5929054A (en) Use of NK-1 receptor antagonists for treating sexual dysfunctions
US5952315A (en) Use of NK-1 receptor antagonists for treating bipolar disorders
EP0942732B1 (fr) Utilisation d'antagonistes du recepteur nk-1 dans le traitement des diskynesies
US5977104A (en) Use of NK-1 receptor antagonists for treating bipolar disorders
AU731674B2 (en) Use of NK-1 receptor antagonists for treating substance use disorders
CA2273807A1 (fr) Utilisation d'antagonistes du recepteur nk-1 dans le traitement des troubles schizophreniques
EP0941092B1 (fr) Utilisation d'antagonistes du recepteur nk-1 dans le traitement des etats depressifs majeurs
US6100256A (en) Use of NK-1 receptors antagonists for treating schizophrenic disorders
EP0942733B1 (fr) Utilisation d'antagonistes du recepteur nk-1 en traitement de troubles cognitifs
CA2273785A1 (fr) Utilisation d'antagonistes du recepteur nk-1 dans le traitement des etats anxieux severes
US6156749A (en) Use of NK-1 receptor antagonists for treating movement disorders
US6271230B1 (en) Use of NK-1 receptor antagonists for treating cognitive disorders
AU731676B2 (en) Use of NK-1 receptor antagonists for treating stress disorders
US6087348A (en) Use of NK-1 receptor antagonists for treating stress disorders
CA2273800A1 (fr) Utilisation d'antagonistes du recepteur nk-1 dans le traitement des etats depressifs majeurs accompagnes d'anxiete

Legal Events

Date Code Title Description
FZDE Discontinued